This study aims to determine whether distributing deworming drugs through routine healthcare services at the first point of contact in the health system is an effective way to prevent and treat worm infections in Western Kenya. This will be compared to the current campaign-based method that operates outside the health system. The main questions it aims to answer are: * Is the alternative method suitable and achievable in the targeted area? * What percentage of the population does this method cover? How does it compare with the current method? * How cost-effective is this alternative method? Researchers will compare outcomes in wards where the integrated method of drug administration is implemented (intervention arm) to wards where the standard campaign-based method is continued (control arm) to answer these questions. Participants from both arms of the study will: * Community members will respond to survey questions on their experience and access levels to deworming drugs. Some will also participate in Focus Group Discussions. * Health facility heads will be interviewed to assess the health facility and collect cost data. * Key stakeholders within the county administration will be engaged in key informant interviews. * Community Health Promoters will participate in Focus Group Discussions.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of primary healthcare facilities achieving high feasibility of integrating STH/SCH treatment into the primary healthcare system, as measured by a multi-domain feasibility questionnaire with a maximum score of 10.
Timeframe: 12 weeks after initiation of STH/SCH treatment integration into the primary healthcare system
Mass drug administration coverage in the target population, comparing reported coverage and survey-based coverage in the intervention and control groups
Timeframe: From enrollment through the endline survey at 3 months after initiation of MDA
Implementation cost of integrating STH/SCH treatment into the primary healthcare system, measured as cost per treated individual in the intervention and control groups
Timeframe: From intervention implementation through the endline assessment at 3 months after initiation of STH/SCH treatment integration, with 5-year projected costs and effects used for the cost-effectiveness analysis